Literature DB >> 950467

In vitro activation of mouse macrophages by rat lymphocyte mediators.

I J Fidler, J H Darnell, M B Budmen.   

Abstract

Macrophage-activating factors (MAF)3 were released by presensitized rat lymphocytes stimulated in vitro with the appropriate antigens. Different supernatants of presensitized rat lymphocytes specifically stimulated in vitro with several different mouse, dog, and rat tumor or normal cells were capable of rendering normal rat and mouse macrophages nonspecifically cytotoxic in vitro to their respective syngeneic tumor cells. The release of active mediators by rat lymphocytes sensitized in vivo was dependent upon immunologically specific recognition of an antigen in vitro. When rat lymphocytes were incubated in vitro with antigens unrelated to the in vivo sensitizing antigens, no release of MAF occurred. Once rat MAF was released, it activated both syngeneic (rat) and xenogeneic (mouse) macrophages to kill tumor cells in vitro. These activated marcophages destroyed all syngeneic tumor targets. Such cytotoxicity was obtained even when the cells used to elicit release of MAF were totally unrelated to the target tumor cells. The data thus demonstrated that MAF can cross strain and even species specificities and can activate macrophages to kill tumors in a nonspecific manner. The cytotoxicity mediated by in vitro activated mouse macrophages decreased with time once the macrophages were removed from MAF; and by 7 days postactivation, the macrophages were not cytotoxic. However, when incubated again with MAF, significant reactivation was observed. This suggested that activation of macrophages in vivo may be a continuous process of lymphocyte-macrophage interaction.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 950467

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Breakdown of articular cartilage proteoglycans by lymphokine-activated macrophages.

Authors:  J Panagides; N Tao
Journal:  Inflammation       Date:  1978-06       Impact factor: 4.092

2.  Kinetics and ultrastructural studies of the induction of rat alveolar macrophage fusion by mediators released from mitogen-stimulated lymphocytes.

Authors:  S Sone; C Bucana; L C Hoyer; I J Fidler
Journal:  Am J Pathol       Date:  1981-05       Impact factor: 4.307

3.  Identification and characterization of a monoclonal antibody to an antigen expressed on activated macrophages.

Authors:  T P Koestler; D Rieman; K Muirhead; R G Greig; G Poste
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

4.  Cytotoxicity of human macrophages for tumor cells. Enhancement by human lymphocyte mediators.

Authors:  D J Cameron; W H Churchill
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

5.  Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human C-reactive protein or crude lymphokine.

Authors:  P S Thombre; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 6.  Immune surveillance and natural resistance: an evaluation.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor.

Authors:  D A Eppstein; Y V Marsh; M van der Pas; P L Felgner; A B Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  The induction of lymphocytes with the capacity to render macrophages cytotoxic in an allogeneic murine system.

Authors:  R A De Weger; E Pels; W Den Otter
Journal:  Immunology       Date:  1982-11       Impact factor: 7.397

9.  In vitro activation of murine Kupffer cells by lymphokines or endotoxins to lyse syngeneic tumor cells.

Authors:  Z L Xu; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1984-12       Impact factor: 4.307

10.  Interactions between human monocytes and tumour cells. Monocytes can either enhance or inhibit the growth and survival of K562 cells.

Authors:  B Davies; S W Edwards
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.